613 resultados para basil
Resumo:
Mode of access: Internet.
Resumo:
Extra engraved title-page, with imprint: Lugud. Batavor. : Apud Adrianum VVijngaerden, & Franciscum Moyarden, 1641.
Resumo:
Mode of access: Internet.
Resumo:
Review
Resumo:
General note: Title and date provided by Bettye Lane.
Resumo:
Compte rendu de la présentation de la pièce « Count Basil » de Joanna Baillie montée par la compagnie Horizon Theatre lors du Congrès 2004 de la North American society for the study of romanticism (NASSR).
Resumo:
Compte rendu de la présentation de la pièce « Count Basil » de Joanna Baillie montée par la compagnie Horizon Theatre lors du Congrès 2004 de la North American society for the study of romanticism (NASSR).
Resumo:
Antitumor, antimicrobial and antioxidant activities of basil were studied, along with its characterization in phenolic compounds, organic acids and soluble sugars. The results placed basil as a valuable candidate for functionalization and conservation of food products, maintaining their nutritional properties, while increasing their shelf life and potential health effects. The basil leaves were then incorporated in "Serra da Estrela Cheese", either in its dehydrated form or as a decoction. The cheeses were then subject to a nutritional evaluation, being characterized for their fatty acids, minerals and CIE color parameters. To assess the combined effects of plant incorporation and storage time, a 2-way ANOVA was used to process the results, further analysed through a linear discriminant analysis. Overall, basil leaves provided antioxidant activity to the cheeses, reduced the moisture, and preserved the unsaturated fatty acids and proteins. Comparing both incorporation types, the decoctions had a higher functionalizing and conservative effect.
Resumo:
Il progetto di questa tesi ha l’obiettivo di analizzare l’effetto dei Campi Elettrici Pulsati (PEF) sulla qualità delle foglie di basilico tailandese, essiccate sottovuoto. Nell’esperimento sono stati utilizzati i Campi Elettrici Pulsati a elettroporazione reversibile, come pretrattamento di essiccazione, e si è visto come questi influenzino la durata del trattamento di essiccazione. Dai risultati si può notare che essi riducono il tempo di processo in campioni sottoposti a 20°C, ma all’aumentare della temperatura tale effetto sembra essere meno significativo, come si può osservare già a 40°C. Una volta che le foglie sono state esposte ai Campi Elettrici Pulsati, vengono lasciate a riposo per 24 ore in un ambiente umido a temperatura ambiente prima di essere essiccate, per raggiungere buoni risultati qualitativi. I campioni, così analizzati, hanno una buona capacità di reidratazione, una bassa conduttività durante il processo di reidratazione e preservano meglio il colore durante l’esperimento, rispetto alle foglie che non sono state sottoposte ai Campi Elettrici Pulsati, né alle successive 24 ore di riposo.
Resumo:
No abstract
Resumo:
Significant progress has been achieved in elucidating the role of the plasma membrane Ca2+-ATPase in cellular Ca2+ homeostasis and physiology since the enzyme was first purified and physiology since the enzyme was first purified and cloned a number of years ago. The simple notion that the PM Ca2+-ATPase controls resting levels of [Ca2+](CYT) has been challenged by the complexity arising from the finding of four major isoforms and splice variants of the Ca2+ pump, and the finding that these are differentially localized in various organs and subcellular regions. Furthermore, the isoforms exhibit differential sensitivities to Ca2+, calmodulin, ATP, and kinase-mediated phosphorylation. The latter pathways of regulation can give rise to activation or inhibition of the Ca2+ pump activity, depending on the kinase and the particular Ca2+ pump isoform. Significant progress is being made in elucidating subtle and more profound roles of the PM Ca2+-ATPase in the control of cellular function. Further understanding of these roles awaits new studies in both transfected cells and intact organelles, a process that will be greatly aided by the development of new and selective Ca2+ pump inhibitors. (C) 1999 Elsevier Science Inc.
Resumo:
Objectives: To establish the prevalence and predictors of genital warts among healthy women presenting for contraceptive advice at two family planning clinics, one in a major Australian city and one in a country town in the same state. Methods: Consecutive consenting attendees (n = 1218)at two family planning clinics in Queensland completed a questionnaire and were examined for genital warts. Results: The point prevalence of visible genital warts was 3.3 per cent in the city clinic and 14.4 per cent in the country town. For half of these clients a finding of warts was unexpected, in that the client was unaware of their presence and presentation to the family planning clinic was not specifically for advice about sexually transmitted infections. The major predictor of a finding of warts was client age, with the highest prevalence in 20- to 25-year-olds. Warts were also commoner amongst smokers in the country town but not in Brisbane. However, no analysed sociodemographic variable predicted a finding of warts of which the client was not aware. Conclusions: Genital warts are common among young women presenting for contraceptive advice. Such women are often unaware that they have warts. Examination for genital warts should be a part of any routine examination of sexually active women, and medical practitioners should be aware of appropriate advice for patients who are found to have genital warts on routine examination.
Resumo:
No abstract
Resumo:
Background The protease-activated receptor 1 (PAR-1), the main platelet receptor for thrombin, represents a novel target for treatment of arterial thrombosis, and SCH 530348 is an orally active, selective, competitive PAR-1 antagonist. We designed TRA.CER to evaluate the efficacy and safety of SCH 530348 compared with placebo in addition to standard of care in patients with non-ST-segment elevation (NSTE) acute coronary syndromes (ACS) and high-risk features. Trial design TRA.CER is a prospective, randomized, double-blind, multicenter, phase III trial with an original estimated sample size of 10,000 subjects. Our primary objective is to demonstrate that SCH 530348 in addition to standard of care will reduce the incidence of the composite of cardiovascular death, myocardial infarction (MI), stroke, recurrent ischemia with rehospitalization, and urgent coronary revascularization compared with standard of care alone. Our key secondary objective is to determine whether SCH 530348 will reduce the composite of cardiovascular death, MI, or stroke compared with standard of care alone. Secondary objectives related to safety are the composite of moderate and severe GUSTO bleeding and clinically significant TIMI bleeding. The trial will continue until a predetermined minimum number of centrally adjudicated primary and key secondary end point events have occurred and all subjects have participated in the study for at least I year. The TRA.CER trial is part of the large phase III SCH 530348 development program that includes a concomitant evaluation in secondary prevention. Conclusion TRA.CER will define efficacy and safety of the novel platelet PAR-1 inhibitor SCH 530348 in the treatment of high-risk patients with NSTE ACS in the setting of current treatment strategies. (Am Heart J 2009; 158:327-34.)